Table 2. Expression levels of miRNAs in the COPD and control group.
| miRNAs | COPD vs. control | ||
|---|---|---|---|
| Fold regulation | 95% CI | P value | |
| hsa-miR-769-5p | 2.0108 | 0.77, 3.26 | 1.000 |
| hsa-miR-181d-5p | 1.6559 | 0.81, 2.50 | 1.000 |
| hsa-miR-501-3p | 1.4094 | 0.61, 2.21 | 0.502 |
| hsa-miR-125b-1-3p | 1.2192 | 0.60, 1.83 | <0.0001 |
| hsa-miR-191-5p | 1.0708 | 0.95, 1.19 | 0.835 |
| hsa-miR-143-3p | 1.0675 | 0.68, 1.46 | 0.536 |
| hsa-miR-26a-5p | 1.0577 | 0.94, 1.18 | 0.835 |
| hsa-miR-23b-3p | 1.0504 | 0.90, 1.20 | 0.522 |
| hsa-miR-30a-5p | 1.0456 | 0.97, 1.12 | 1.000 |
| hsa-miR-151a-3p | 1.0011 | (0.89, 1.12) | 0.537 |
| hsa-miR-361-3p | −1.0044 | (0.65, 1.34) | 0.835 |
| hsa-miR-28-3p | −1.011 | (0.86, 1.12) | 1.000 |
| hsa-miR-148a-3p | −1.0189 | (0.83, 1.14) | 0.679 |
| hsa-miR-30e-3p | −1.0218 | (0.74, 1.21) | <0.0001 |
| hsa-miR-361-5p | −1.0354 | (0.58, 1.35) | 0.302 |
| hsa-miR-181b-5p | −1.0709 | (0.83, 1.04) | 0.659 |
| hsa-miR-101-3p | −1.1287 | (0.74, 1.03) | 0.679 |
| hsa-miR-660-5p | −1.1339 | (0.62, 1.15) | 1.000 |
| hsa-miR-181c-5p | −1.1594 | (0.61, 1.11) | 0.831 |
| hsa-miR-181a-2-3p | −1.5998 | (0.28, 0.97) | 0.008 |
Fold change (2−ÄÄCt) is normalized gene expression. (2−ÄCt) in test sample divided the normalized gene expression (2−ÄCt) in the control sample. Quantitation was normalized to reference control. COPD, chronic obstructive pulmonary disease; CI, confidence interval.